Annovis Bio (ANVS) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01Our recurring operating losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about our ability to continue as a going concern, if we are unable to obtain additional financings
2. 02The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2024 contains an explanatory paragraph relating to our ability to continue as a going concern
3. 03We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability
4. 04We will require substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of buntanetap
5. 05Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates
6. 06We have limited operating history and no history of commercializing pharmaceutical products
7. 07Our ability to use our tax net operating losses is uncertain
8. 08Inflation could adversely affect our business and results of operations
9. 09Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price

Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

1. 10We are heavily dependent on the success of buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed
2. 11If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired
3. 12Business disruptions could harm our ability to complete or could materially delay our clinical trials, as well as cause disruptions to the FDA and other governmental authorities
4. 13Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome
5. 14The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for buntanetap or any other product candidates, our business will be substantially harmed
6. 15Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
7. 16We may develop buntanetap and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks
8. 17Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control
9. 18Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials
10. 19business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock
11. 20Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales
12. 21The market opportunities for buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations
13. 22We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates. Further, even if marketing approval is obtained, we have no experience as a company in commercializing products
14. 23Even if we obtain FDA approval for buntanetap or any other product candidates in the United States, we may never obtain approval for or commercialize buntanetap or any other product candidates in any other jurisdiction, which would limit our ability to realize their full market potential
15. 24Even if we obtain regulatory approval for buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties
16. 25The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
17. 26We may seek a Breakthrough Therapy designation for buntanetap from the FDA in PD and AD. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process
18. 27Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit, delay or cease commercialization of any products that we may develop
19. 28Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities

Risks Related to Commercialization

1. 29We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively
2. 30Even if buntanetap or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would adversely affect our business
3. 31If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing buntanetap, if approved
4. 32A variety of risks associated with operating internationally could materially adversely affect our business

Risks Related to Our Dependence on Third Parties

1. 33We currently rely and in the future intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 34Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set
2. 35Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there may be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition
3. 36Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
4. 37Any clinical trial programs we conduct or research collaborations we enter into in the EEA may subject us to the General Data Protection Regulation
5. 38We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities
6. 39Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows

Risks Related to Our Intellectual Property

1. 40If we are unable to obtain additional patent protection to prolong the patent life of our product candidates, we may not be able to continue development of our product candidates
2. 41We may be subject to claims challenging the inventorship of our patents and other intellectual property
3. 42We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates
4. 43Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
5. 44Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 45We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
7. 46If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and under similar legislation in foreign countries, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed
8. 47obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially
9. 48Intellectual property rights do not address all potential threats to our competitive advantage
10. 49We have not yet registered our trademarks in the United States or other jurisdictions. Failure to secure such registrations could adversely affect our business
11. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
12. 51We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property
13. 52Our proprietary information may be lost, or we may suffer security breaches

Risks Related to Our Employees, Managing Our Growth and Our Operations

1. 53Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
2. 54We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 55We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
4. 56We may seek to enter into collaborations, license agreements and other similar arrangements in the future, and may not be successful in doing so
5. 57Our business and operations would suffer in the event of failures involving our information technology systems, or those of any of our service providers
6. 58Disruption, failure or cybersecurity breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations

Risks Related to Our Common Stock

1. 59The market price of our common stock has been volatile and fluctuated substantially in the past and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock
2. 60Our failure to meet the New York Stock Exchange’s continued listing requirements could result in a delisting of our common stock
3. 61We have been subject to securities class action litigation in the past and could be subject to such litigation in the future
4. 62Our directors, executive officers and certain stockholders own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant control over matters subject to stockholder approval
5. 63If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline
6. 64Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders
7. 65We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices
8. 66We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors
9. 67Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management